PDF   Print   View All
July 11, 2002
Philadelphia, PA, Thursday, July 11, 2002: Philadelphia, PA, July 11, 2002 – Hemispherx Biopharma, Inc. (AMEX:HEB), a leading company in the experimental-stage development of immune based therapies primarily addressing the diseases of HIV/AIDS and Chronic Fatigue Syndrome announced today that on Thursday July 18, 2002 at 11:00 am Eastern Time it will conduct a conference call to review the new data as presented at the XIV International AIDS Conference, the world’s largest HIV/AIDS meeting, held in Barcelona, Spain, July 7-12.

Dr. William A. Carter, Chief Executive Officer, Dr. David R. Strayer, Medical Director, and Dr. David Blick, Principle Independent Investigator who presented the data in Barcelona, will host a conference call with analysts and investors to review the details of the new data as presented at the International Aids Conference in Barcelona. The latest results have been presented about its two phase IIb clinical trials for HIV/AIDS, one Strategic Treatment Intervention (STI) and one experimental Salvage Therapy.

Dr. Carter and Dr. Strayer will also be fielding questions at the end of the conference call.

On the day of the conference call, interested parties may dial into the call at least 10 minutes prior and the operator will connect them to the call. Investors should be prepared to provide their name, company and email address.

Interested parties in the U.S may access the call live by dialing (888) 566 – 5901 or international callers may access the conference by dialing 630 395 0130, and mentioning Wesley L. Stanton as the Conference Call Leader and the Password, which is 111333. An audio replay of the conference call will also be available for one month on www.hemispherx.net in the Investor Relations section.

A telephone replay of the conference call will also be available through Friday July 26th, 2002. Interested parties wanting to access the telephone replay should call (800) 945 - 7474 in the U.S. and 402 220 3569 for international callers.


Hemispherx Biopharma, Inc is a biopharmaceutical company that focuses on the innovative development of ribonucleic acid (RNA) drug technologies intended to enhance the natural anti-viral defense system of the human body, representing a potential new class of pharmaceutical products. Its primary product, Ampligen, is in two phase IIb clinical trials for HIV/AIDS, one experimental Salvage Therapy and one Strategic Treatment Intervention (STI), and a phase III clinical trial for Chronic Fatigue Syndrome (CFS).

Hemispherx Biopharma, Inc., Investor Relations
(215) 988-1712, Fax: (215) 988-1554

Dianne Will, Investor Relations
(518) 398-6222, Fax: (518) 398-6223

Robert Giordano, MRB Institutional Investors, MRB
(212) 495-0200, Fax: (212) 495-0746

HEB's Web Site: www.hemispherx.net

Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company’s filings with the Securities and Exchange Commission. Accordingly, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company’s judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.